Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCND1 | P24385 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PLAU | P00749 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3616878 | 0.83 | CDK4 (0.76) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL11366447 | 0.81 | CDK4 (1.00) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL4863420 | 0.79 | CDK4 (0.78) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL945970 | 0.79 | CDK4 (0.71) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL3477752 | 0.78 | CDK4 (0.81) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL1629560 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL13227451 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL3887125 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL1616222 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C | |
| SCHEMBL2076869 | 0.77 | CDK4 (0.68) | CDK4CCND1KMT2AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2629777-B1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-12-19 | — | — | EP | claimed |
| CN-107295799-A | Parg inhibiting compounds | 癌症研究科技有限公司 | 2017-10-24 | — | — | CN | claimed |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-08-29 | — | — | US | claimed |
| EP-2629777-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-28 | — | — | EP | claimed |
| WO-2012054364-A2 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-26 | — | — | WO | claimed |
| EP-1416933-B8 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1773780-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-09 | — | — | EP | claimed |
| EP-1773780-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012227-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| EP-1416933-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | Amgem, Inc. (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| US-5049181-A | Novel herbicidally active n-phenyl-azoles | CIBA-GEIGY CORPORATION (US) | 1991-09-17 | — | — | US | claimed |
| EP-0201735-B1 | N-INDOLYLETHYL SULFON AMIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1990-09-12 | — | — | EP | claimed |
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| CN-112673095-A | Plants containing elite event EE-GM5, and methods and kits for identifying said event in biological samples, and treatment thereof | 巴斯夫农业种子解决方案美国有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112673096-A | Plants containing elite event EE-GM4, and methods and kits for identifying said event in biological samples, and treatment thereof | 巴斯夫农业种子解决方案美国有限责任公司 | 2021-04-16 | — | — | CN | disclosed |
| EP-0011277-A1 | Dechloromaytansinoids, their production and use and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0011276-A1 | Maytansinoids, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1980-05-28 | — | — | EP | disclosed |
| EP-0010735-A1 | Maytansinoids, their production and pharmaceutical compositions containing them | Takeda Chemical Industries, Ltd. (JP) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288338-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | CDK4 3572/4885CCND1 4246/4885KMT2A 3525/4885 |
| US-20130225577-A1 | BICYCLIC DIAMINES AS JANUS KINASE INHIBITORS | JAK1, JAK2, JAK3 | CDK4 273/4885CCND1 411/4885KMT2A 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.